Springworks Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Form 4: SpringWorks Therapeutics Director Disposes of Shares and Options Following Merger with Merck KGaA
A director of SpringWorks Therapeutics, Inc. has reported the disposition of common stock and stock options following the company's acquisition by Merck KGaA for $47.00 per share in cash.
Form 4: SpringWorks Therapeutics COO Disposes of Equity Holdings Following Merck KGaA Merger Completion
SpringWorks Therapeutics' Chief Operating Officer, Edris Badreddin, disposed of all beneficial ownership in the company's securities, including common stock, restricted stock units, performance share units, and stock options, as a result of the company's acquisition by Merck KGaA for $47.00 per share.
Form 4: SpringWorks Therapeutics Director Disposes of Shares and Options Following Merger with Merck KGaA
Daniel Lynch, a Director at SpringWorks Therapeutics, Inc., has reported the disposition of all his common stock, restricted stock units, and stock options as a result of the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025.
SpringWorks Therapeutics, Inc. has completed its merger with Merck KGaA, Darmstadt, Germany, resulting in the conversion of all outstanding shares, restricted stock units, and stock options into cash or cash-based awards.
A director of SpringWorks Therapeutics, Inc. reported the complete disposition of common stock, restricted stock units, and stock options as a result of the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, at a cash consideration of $47.00 per share.
SpringWorks Therapeutics, Inc. Director Alan Fuhrman has disposed of all his common stock and stock options, totaling 24,727 shares and 78,755 options, respectively, as a result of the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, at a cash consideration of $47.00 per share.
SpringWorks Therapeutics' Chief Scientific Officer, Lin Tai-An, has reported the disposition of all common stock, restricted stock units, performance share units, and stock options following the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, at a cash consideration of $47.00 per share.
SpringWorks Therapeutics' Chief Commercial Officer, Bhavesh Ashar, converted all common stock, restricted stock units, performance share units, and stock options into cash or cash-based awards following the company's acquisition by Merck KGaA.
SpringWorks Therapeutics' Chief Medical Officer, James Cassidy, disposed of all beneficial ownership in the company's securities following the completion of its acquisition by Merck KGaA for $47.00 per share.
SpringWorks Therapeutics, Inc. has been acquired by Merck KGaA, Darmstadt, Germany, with all outstanding shares converted into a cash right of $47.00 per share, as detailed in a director's Form 4 filing.
SpringWorks Therapeutics' Chief Accounting Officer, Michael Nofi, disposed of all his common stock, restricted stock units, performance share units, and stock options as a result of the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, with shares converted to $47.00 cash per share.
Daniel Pichl, Chief People Officer of SpringWorks Therapeutics, Inc., disposed of all his beneficial ownership in the company's common stock, restricted stock units, performance share units, and stock options as a result of the company's acquisition by Merck KGaA, Darmstadt, Germany.
SpringWorks Therapeutics, Inc.'s Chief Financial Officer, Francis I. Perier Jr., has reported the disposition of all his beneficial ownership in the company's securities, including common stock, restricted stock units, performance share units, and stock options, as a direct result of the company's merger with EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany.
Form 4: SpringWorks Therapeutics CEO Reports Full Disposal of Equity Holdings Post-Merger with Merck KGaA
SpringWorks Therapeutics, Inc. CEO Saqib Islam reported the disposal of all his beneficial ownership in company common stock, restricted stock units, performance share units, and stock options effective July 1, 2025, as a result of the company's merger with Merck KGaA.
Form 4: SpringWorks Therapeutics General Counsel Disposes of Equity Following Merger with Merck KGaA
Herschel S. Weinstein, General Counsel and Secretary of SpringWorks Therapeutics, Inc., disposed of all his beneficial ownership in the company's equity and derivative securities effective July 1, 2025, as a result of the company's merger with Merck KGaA.
Director Daniel Lynch acquired 10,060 shares of SpringWorks Therapeutics stock through a restricted stock unit (RSU) grant.
Form 4: SpringWorks Therapeutics Director Freda Lewis-Hall Reports Acquisition and Disposal of Shares
Director Freda Lewis-Hall reports acquisition of 10,060 shares and disposal of 24,727 shares of SpringWorks Therapeutics common stock on May 14, 2025, related to restricted stock units.
Director Julie Hambleton received 10,060 shares of SpringWorks Therapeutics restricted stock units and disposed of 14,155 shares on May 14, 2025.
Director Alan Fuhrman of SpringWorks Therapeutics receives a grant of restricted stock units (RSUs) and disposes of common stock.
Director Carlos Alban received a grant of 10,060 restricted stock units (RSUs) from SpringWorks Therapeutics on May 14, 2025.
Director Martin Mackay received 10,060 restricted stock units from SpringWorks Therapeutics on May 14, 2025, according to a Form 4 filing.
Badreddin Edris, Chief Operating Officer of SpringWorks Therapeutics, executed multiple sales of common stock on March 3, 2025, under a pre-arranged trading plan.
CEO Saqib Islam of SpringWorks Therapeutics executed multiple sales of common stock under a pre-arranged 10b5-1 trading plan.
SpringWorks Therapeutics CEO Saqib Islam sold shares of common stock on February 20, 2025, under a pre-arranged trading plan.
Bhavesh Ashar, Chief Commercial Officer of SpringWorks Therapeutics, sold 1,016 shares of common stock at an average price of $61.1891 under a pre-arranged trading plan.
Director Daniel Lynch sold shares of SpringWorks Therapeutics (SWTX) on February 20, 2025, under a pre-arranged trading plan.
SpringWorks Therapeutics CEO Saqib Islam sold 10,672 shares of common stock at an average price of $59.9222 on February 14, 2025, under a pre-arranged trading plan.
Director Daniel Lynch sold 400 shares of SpringWorks Therapeutics (SWTX) common stock at $60 per share on February 14, 2025, according to a Form 4 filing.
CEO Saqib Islam reports acquisition of SpringWorks Therapeutics shares through performance restricted stock units (PSUs) and disposal of shares to cover tax obligations.
Daniel Pichl, Chief People Officer at SpringWorks Therapeutics, executed stock options and sold shares under a pre-arranged trading plan.